Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Tuberculosis
Conditions
Pulmonary Tuberculosis
Trial Timeline
Jan 1, 2008 → Feb 1, 2014
NCT ID
NCT00864383About Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin is a phase 3 stage product being developed by Sanofi for Pulmonary Tuberculosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00864383. Target conditions include Pulmonary Tuberculosis.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Tuberculosis were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00864383 | Phase 3 | Completed |
Competing Products
20 competing products in Pulmonary Tuberculosis